Edaravone Oral Suspension for Consistent Dosing in Dysphagia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for ALS, such as edaravone injections, pose challenges for patients with dysphagia and caregivers due to administration difficulties and variability in drug concentration, necessitating a more accessible and stable oral formulation.
Innovation Solution
A suspension formulation of edaravone particles in water with dispersants and optional thickening agents, designed to maintain a well-dispersed state and reduce variability in drug concentration, suitable for patients with dysphagia and ensuring stable drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If edaravone injection is used for ALS treatment, then therapeutic effect is achieved, but administration difficulty and variability in drug concentration occur
Solution Approach 1:
The patent transforms edaravone from a parenteral injection formulation to an oral suspension formulation, changing the administration route parameter. This involves optimizing particle size (D50: 10-100 μm), dispersant concentration (0.1-1% w/v), and suspension viscosity to achieve consistent drug delivery via oral route, resolving the contradiction between administration ease and concentration consistency
Solution Approach 2:
The patent introduces dispersants as intermediary substances to maintain uniform distribution of edaravone particles in the oral suspension. The dispersant prevents particle aggregation and ensures consistent drug concentration throughout the suspension, addressing the variability issue while enabling easier oral administration
2Reliability
If oral suspension is formulated with dispersants, then drug concentration stability is improved, but formulation complexity increases
Solution Approach 1:
The patent optimizes the dispersant concentration within a specific range (0.1-1% w/v) to achieve adequate particle dispersion without excessive formulation complexity. This parameter optimization ensures drug concentration stability while maintaining a simple, clinically practical formulation that does not require complex manufacturing processes
3Speed
If edaravone particle size is reduced, then dissolution rate and absorption are improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies a particle size range (D50: 10-100 μm) that balances dissolution rate improvement with manufacturability. This parameter range is optimized to achieve adequate dissolution and absorption while remaining feasible for standard pharmaceutical manufacturing processes, avoiding excessive precision requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The suspension provides a stable and effective oral administration of edaravone, achieving drug concentrations comparable to injections while reducing burden on patients and caregivers, with minimal aspiration risk and consistent drug effect.
Implementation Method 1
A suspension formulation of edaravone particles in water with dispersants and optional thickening agents, designed to maintain a well-dispersed state
Data Source
AI summary
An edaravone suspension for human oral administration includes edaravone particles. a dispersant, and water.